Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nasopharyngeal cancer: a promising future.

× No keyword cloud information.

15 in total

1. [Adjuvant chemotherapy with cisplatin and gemcitabine after radiochemotherapy with curative intent does not improve relapse-free survival in nasopharyngeal cancer patients with persistently detectable EBV DNA].

Authors: Christoph Willich; Thomas B Brunner
Journal: Strahlenther Onkol Date: 2019-01 Impact factor: 3.621

2. Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.

Authors: Fangzheng Wang; Chuner Jiang; Zhimin Ye; Quanquan Sun; Tongxin Liu; Min Xu; Peng Wu; Kaiyuan Shi; Bin Long; Aizawa Rihito; Sakamoto Masoto; Zhenfu Fu
Journal: Oncotarget Date: 2017-04-21

3. Phase I/II study of induction chemotherapy plus concurrent chemotherapy and SMART-IMRT-based radiotherapy in locoregionally-advanced nasopharyngeal cancer.

Authors: Ting-Yong Fan; Jun Xing; Jie Lu; Tong-Hai Liu; Min Xu; Ying-Jie Zhang; Qian Shao; Jian-Bin Li; Jin-Ming Yu
Journal: Oncol Lett Date: 2013-01-15 Impact factor: 2.967

4. Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials.

Authors: Yu-Pei Chen; Rui Guo; Na Liu; Xu Liu; Yan-Ping Mao; Ling-Long Tang; Guan-Qun Zhou; Ai-Hua Lin; Ying Sun; Jun Ma
Journal: J Cancer Date: 2015-07-17 Impact factor: 4.207

5. Inhibition of nasopharyngeal carcinoma cell proliferation and synergism of cisplatin with silvestrol and episilvestrol isolated from Aglaia stellatopilosa.

Authors: Maelinda Daker; Jiun-Tzen Yeo; Norhasimah Bakar; Asma' Saiyidatina Aishah Abdul Abdul Rahman; Munirah Ahmad; Tiong-Chia Yeo; Alan Soo-Beng Khoo
Journal: Exp Ther Med Date: 2016-03-29 Impact factor: 2.447

6. Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone.

Authors: Yu-Pei Chen; Wen-Na Zhang; Ling-Long Tang; Yan-Ping Mao; Xu Liu; Lei Chen; Guan-Qun Zhou; Hai-Qiang Mai; Jian-Yong Shao; Wei-Hua Jia; Tie-Bang Kang; Mu-Sheng Zeng; Ying Sun; Jun Ma
Journal: BMC Cancer Date: 2015-11-24 Impact factor: 4.430

7. Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis.

Authors: Wang Fangzheng; Jiang Chuner; Ye Zhimin; Sun Quanquan; Liu Tongxin; Xu Min; Wu Peng; Long Bin; Masoto Sakamoto; Wang Yuezhen; Yan Fengqin; Fu Zhenfu; Jiang Yangming
Journal: Oncotarget Date: 2017-10-06

8. Addition of 5-fluorouracil to docetaxel/cisplatin does not improve survival in locoregionally advanced nasopharyngeal carcinoma.

Authors: Wang Fangzheng; Jiang Chuner; Sun Quanquan; Ye Zhimin; Liu Tongxin; Liu Jiping; Masoto Sakamoto; Wu Peng; Shi Kaiyuan; Qin Weifeng; Fu Zhenfu; Jiang Yangming
Journal: Oncotarget Date: 2017-12-14

9. Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis.

Authors: Fangzheng Wang; Quanquan Sun; Chuner Jiang; Tongxin Liu; Aizawa Rihito; Sakamoto Masoto; Yuezhen Wang; Zhenfu Fu; Ming Chen
Journal: J Cancer Date: 2018-01-01 Impact factor: 4.207